Your Story, Everywhere Investors Are Looking.

B2i Digital's media distribution network places your company's content across the financial publications and investor platforms that matter most.

When investors research a public company, they look in a dozen places before they ever visit its website. B2i Digital makes sure your story is already there, waiting for them. Through our media distribution network, we position your content across leading financial news sites, investor platforms, and content channels so your company shows up wherever the market is paying attention.

Our clients' content has appeared on platforms including these, among many others.


Recent premium placements include:


Plus local television station sites across the largest U.S. media markets, from New York to San Francisco.

0+
News, broadcast, and trade outlets carrying a single client announcement
0M+
Combined monthly audience across those outlets
0M+
Investors and market participants following our own channels

This is not a single press release blasted once and forgotten.

Announcements are also ingested into professional news databases including the Bloomberg Terminal, Moody's Analytics NewsEdge, Muck Rack, and Crunchbase. It is a coordinated, ongoing distribution effort designed to build a lasting, searchable presence for your company, everywhere investors do their research. 

Audience figures reported by our media distribution partners.

Where a client’s news lands

B2i in the middle. Six families of media and partners linking in.

Six families

Push and pull

Five families are where client news runs. The sixth is who links back to us: banks, conference partners and 35 public company client sites.

Financial and business media

14 of 16 sites shown

Investor data and trading platforms

9 of 16 platforms shown

Broadcast television and radio

12 of 53 stations shown

110+ network affiliate sites, coast to coast.

Regional news and daily press

6 of 16 papers shown

225+ USA TODAY Network newspaper sites.

Trade and industry press

8 of 14 publications shown

Banks, partners and client sites

11 of 46 shown

Plus Investing.com and 35 public company client sites.

800+

outlets reached by one announcement

330M+

combined monthly audience

1.7M+

social followers

The Power Is in the Combination

A single client announcement reaches more than 800 news, broadcast, and trade outlets with a combined audience of more than 330 million unique monthly visitors. No single tactic carries the day. It is the compounding effect of all of them, working in concert, that puts your company in front of investors again and again. 

Media distribution

News and trade outlets

Social following

1.7M+ investors and participants

Email

Nearly 70,000 opt-in investors

Paid advertising

Investor-targeted

Our own website

High authority, indexed

SMS

Client news reinforced by text, opt-in and growing

Within the micro and small cap arena we serve, B2i Digital ranks among the highest authority publishing platforms catering to public companies of our clients’ size.

Built Around Your Objectives

Some CEOs come to us for reach: maximum awareness, everywhere investors are paying attention. Others are hyper-focused on one thing: getting in front of the right investors one-on-one. We built our platform for both. Take the reach on its own, go straight for the meetings, or run the full path from first impression to final conversation. 

The Matchmaking Funnel:
From Millions to One on One

Real capital gets committed in one on one conversations. Everything we do is built to carry your company down that path.

800+ OUTLETS · 330M+ THE REACH HUNDREDS OF INVESTORS THE ROOM WHERE CAPITAL COMMITS THE MEETING

THE REACH

A company's biggest announcements can reach more than 800 news, broadcast, and trade outlets with a combined monthly audience of more than 330 million, reinforced across our social channels, email, SMS, and paid campaigns.

THE ROOM

At our investor conferences and events, hundreds of engaged investors see your company present directly. 

THE MEETING

The one on one conversations with real investors that every public company is ultimately working toward. We can set them up because we know the room: a rolodex of 235,000+ capital markets contacts, by name. 

This is what it means to be The Capital Markets Matchmaker℠. From Marketing to Meetings℠, we carry your story the full distance, from millions of impressions to the handful of conversations that change your company's trajectory. 

Meet Investors, Public Companies, and Industry Experts Where They Are

Investors, executives, and advisors all spend time on different digital platforms throughout the day. B2i Digital’s strategy is built around reaching those audiences where they already consume information and engage online. That approach has helped the company build a community of more than 1.7 million followers across all leading social media platforms.

Latest Press Coverage

See the latest B2i Digital press releases and how our announcements are carried across leading financial platforms, broadcast affiliates and trade publications.

 

OpenPR openpr.com Rocket Doctor AI will present at the National Investment Banking Association's 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026. CEO Essam Hamza will give an overview of the physician-built AI healthcare company's platform, recent milestones and growth strategy. Rocket Doctor AI is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com TOP Ships closed its acquisition of three companies, each holding a shipbuilding contract for a high-specification, scrubber-fitted MR product tanker due for delivery in 2029. The vessels have secured five-year time charters with an oil major, with an option to extend for one additional year. TOP Ships is a B2i Digital Featured Company. Read Press Release Pinion Newswire pinionnewswire.com ZenaTech CEO Shaun Passley issued a letter to shareholders providing a business update and outlook. Drone as a Service generated C$8.6 million, or nearly 93% of second-quarter revenue, as the company expanded its operating platform and defense technology portfolio. ZenaTech is a B2i Digital Featured Company. Read Press Release TechFinancials techfinancials.co.za TOP Ships closed its acquisition of three companies, each holding a shipbuilding contract for a high-specification, scrubber-fitted MR product tanker due for delivery in 2029. The vessels have secured five-year time charters with an oil major, with an option to extend for one additional year. TOP Ships is a B2i Digital Featured Company. Read Press Release Abilene Reporter-News reporternews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Amarillo Globe-News amarillo.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Argus Leader argusleader.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Asbury Park Press app.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Athens Banner-Herald onlineathens.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Athens Banner-Herald onlineathens.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Athens Banner-Herald onlineathens.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Battle Creek Enquirer battlecreekenquirer.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Beaver County Times timesonline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Canton Repository cantonrep.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Cape Cod Times capecodtimes.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Chillicothe Gazette chillicothegazette.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Coldwater Daily Reporter thedailyreporter.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Corpus Christi Caller-Times caller.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Coshocton Tribune coshoctontribune.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Courier & Press courierpress.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Courier & Press courierpress.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Courier & Press courierpress.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Courier News mycentraljersey.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Daily Comet dailycomet.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Daily Tribune wisconsinrapidstribune.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Daytona Beach News-Journal Online news-journalonline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Daytona Beach News-Journal Online news-journalonline.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Daytona Beach News-Journal Online news-journalonline.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Democrat and Chronicle democratandchronicle.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Democrat and Chronicle democratandchronicle.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Democrat and Chronicle democratandchronicle.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com Rocket Doctor AI will present at the National Investment Banking Association's 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026. CEO Essam Hamza will give an overview of the physician-built AI healthcare company's platform, recent milestones and growth strategy. Rocket Doctor AI is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Enterprise News enterprisenews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Erie Times-News goerie.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com TOP Ships closed its acquisition of three companies, each holding a shipbuilding contract for a high-specification, scrubber-fitted MR product tanker due for delivery in 2029. The vessels have secured five-year time charters with an oil major, with an option to extend for one additional year. TOP Ships is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com Rocket Doctor AI will present at the National Investment Banking Association's 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026. CEO Essam Hamza will give an overview of the physician-built AI healthcare company's platform, recent milestones and growth strategy. Rocket Doctor AI is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Fort Collins Coloradoan coloradoan.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Gadsden Times gadsdentimes.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Great Falls Tribune greatfallstribune.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Green Bay Press-Gazette greenbaypressgazette.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Hattiesburg American hattiesburgamerican.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Hendersonville Times-News blueridgenow.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Herald Times Reporter htrnews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Herald-Mail Media heraldmailmedia.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Hillsdale Daily News hillsdale.net Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Independent Mail independentmail.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release IndyStar indystar.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release IndyStar indystar.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release IndyStar indystar.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Journal and Courier jconline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Journal and Courier jconline.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Journal and Courier jconline.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Journal Sentinel jsonline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Knoxville News Sentinel knoxnews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Lansing State Journal lansingstatejournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Lebanon Daily News ldnews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Lebanon Daily News ldnews.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Lebanon Daily News ldnews.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Livingston Daily Press & Argus livingstondaily.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Mansfield News Journal mansfieldnewsjournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Monroe News monroenews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Montgomery Advertiser montgomeryadvertiser.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com TOP Ships closed its acquisition of three companies, each holding a shipbuilding contract for a high-specification, scrubber-fitted MR product tanker due for delivery in 2029. The vessels have secured five-year time charters with an oil major, with an option to extend for one additional year. TOP Ships is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com Rocket Doctor AI will present at the National Investment Banking Association's 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026. CEO Essam Hamza will give an overview of the physician-built AI healthcare company's platform, recent milestones and growth strategy. Rocket Doctor AI is a B2i Digital Featured Company. Read Press Release New Bedford Standard-Times southcoasttoday.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release News Herald portclintonnewsherald.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Ocala StarBanner ocala.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Ocala StarBanner ocala.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Oshkosh Northwestern thenorthwestern.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Palladium-Item pal-item.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Palladium-Item pal-item.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Palladium-Item pal-item.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Panama City News Herald newsherald.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Peoria Journal Star pjstar.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Petoskey News-Review petoskeynews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release PhillyBurbs phillyburbs.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Poughkeepsie Journal poughkeepsiejournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Press & Sun-Bulletin pressconnects.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Public Opinion publicopiniononline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Pueblo Chieftain chieftain.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Rockford Register Star rrstar.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release St. Cloud Times sctimes.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Standard-Times gosanangelo.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Star-Gazette stargazette.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Stevens Point Journal stevenspointjournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Sturgis Journal sturgisjournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Taunton Daily Gazette tauntongazette.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release TechBullion techbullion.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release TechBullion techbullion.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release TechFinancials techfinancials.co.za Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release TechFinancials techfinancials.co.za The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Telegraph-Forum bucyrustelegraphforum.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Advocate newarkadvocate.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Asheville Citizen Times citizen-times.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com TOP Ships closed its acquisition of three companies, each holding a shipbuilding contract for a high-specification, scrubber-fitted MR product tanker due for delivery in 2029. The vessels have secured five-year time charters with an oil major, with an option to extend for one additional year. TOP Ships is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com Rocket Doctor AI will present at the National Investment Banking Association's 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026. CEO Essam Hamza will give an overview of the physician-built AI healthcare company's platform, recent milestones and growth strategy. Rocket Doctor AI is a B2i Digital Featured Company. Read Press Release The Clarion-Ledger clarionledger.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Commercial Appeal commercialappeal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Courier-Journal courier-journal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Courier-Journal courier-journal.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Courier-Journal courier-journal.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Daily Journal thedailyjournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Daily News Journal dnj.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Daily Times delmarvanow.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Des Moines Register desmoinesregister.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Enquirer cincinnati.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Evening Sun eveningsun.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Fayetteville Observer fayobserver.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Florida Times-Union jacksonville.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Florida Times-Union jacksonville.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Florida Times-Union jacksonville.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Greenville News greenvilleonline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Holland Sentinel hollandsentinel.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Hutchinson News hutchnews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Ithaca Journal ithacajournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Jackson Sun jacksonsun.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Marion Star marionstar.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The News Leader newsleader.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The News-Messenger thenews-messenger.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The News-Star thenewsstar.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Patriot Ledger patriotledger.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Patriot Ledger patriotledger.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Patriot Ledger patriotledger.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Providence Journal providencejournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Reporter fdlreporter.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Sheboygan Press sheboyganpress.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The State Journal-Register sj-r.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Times shreveporttimes.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Town Talk thetowntalk.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Tuscaloosa News tuscaloosanews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Times Herald thetimesherald.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Times Herald-Record recordonline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Times Record News timesrecordnews.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Times Recorder zanesvilletimesrecorder.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Utica Observer Dispatch uticaod.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Ventura County Star vcstar.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Ventura County Star vcstar.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Visalia Times-Delta visaliatimesdelta.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Visalia Times-Delta visaliatimesdelta.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Visalia Times-Delta visaliatimesdelta.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Wausau Daily Herald wausaudailyherald.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release York Daily Record ydr.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Athens Banner-Herald onlineathens.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Benzinga benzinga.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Canton Repository cantonrep.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Courier & Press courierpress.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Daytona Beach News-Journal Online news-journalonline.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Democrat and Chronicle democratandchronicle.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Detroit Free Press freep.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release EIN Presswire einpresswire.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release FinancialContent financialcontent.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release FinanzWire finanzwire.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Florida Today floridatoday.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Gainesville Sun gainesville.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release IndyStar indystar.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Insider Monkey insidermonkey.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Journal and Courier jconline.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Lebanon Daily News ldnews.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release MyMotherLode money.mymotherlode.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release Ocala StarBanner ocala.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release OpenPR openpr.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release OpenPR openpr.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Palladium-Item pal-item.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Pensacola News Journal pnj.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Pinion Newswire pinionnewswire.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Salinas Californian thecalifornian.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Savannah Morning News savannahnow.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Tallahassee Democrat tallahassee.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release TechBullion techbullion.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release TechFinancials techfinancials.co.za DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Chronicle-Journal markets.chroniclejournal.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Courier-Journal courier-journal.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Daily Record dailyrecord.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Desert Sun desertsun.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Detroit News detroitnews.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Enquirer cincinnati.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Florida Times-Union jacksonville.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Globe and Mail theglobeandmail.com Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia. The resubmission includes manufacturing data from a new third-party drug product vendor, and the company expects FDA acceptance within 30 days with a new PDUFA date six months later. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release The Globe and Mail theglobeandmail.com ZenaTech reported second-quarter 2026 revenue of C$9.3 million, up 316% year over year, and first-half revenue of C$17.7 million, up 425%. Growth was driven mainly by its Drone as a Service segment, and the company delivered its seventh consecutive quarter of sequential revenue growth. ZenaTech is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Northwest Florida Daily News nwfdailynews.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Patriot Ledger patriotledger.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Stockton Record recordnet.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Topeka Capital-Journal cjonline.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Treasure Coast tcpalm.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Ventura County Star vcstar.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Visalia Times-Delta visaliatimesdelta.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release WebDisclosure webdisclosure.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release WebDisclosure webdisclosure.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Yahoo Finance finance.yahoo.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Akron Beacon Journal beaconjournal.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Athens Banner-Herald onlineathens.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Canton Repository cantonrep.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release CityBuzz citybuzz.co Investors can hear directly from seven AI and technology companies at the AI & Tech Virtual Investor Conference on October 1, 2026. The online event, hosted by Virtual Investor Conferences, features live 30-minute presentations and audience Q&A across semiconductors, data centers, battery materials and fintech. B2i Digital is the Official Marketing Partner, highlighting the conference to its investor and media network. Read Press Release CityBuzz citybuzz.co The invitation-only ROTH Emerging Nuclear Technology Conference brings institutional investors together with nuclear companies in New York City on October 1, 2026. The article ties the event to rising power demand from artificial intelligence, with companies spanning uranium mining, fuel cycle, small modular reactors, microreactors and fusion. B2i Digital is serving as Marketing Partner for the ROTH Capital Partners conference. Read Press Release Courier & Press courierpress.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Daytona Beach News-Journal Online news-journalonline.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Democrat and Chronicle democratandchronicle.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Detroit Free Press freep.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release EIN Presswire einpresswire.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release EQS News eqs-news.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release FinancialContent financialcontent.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release FinancialContent financialcontent.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release FinanzWire finanzwire.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Florida Today floridatoday.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Gainesville Sun gainesville.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release GlobeNewswire globenewswire.com ROTH Capital Partners will host its inaugural Emerging Nuclear Technology Conference on October 1, 2026 at 1 Hotel Central Park in New York City. The invitation-only event connects institutional investors with public and private companies from uranium mining and the fuel cycle to next-generation reactors and fusion. The conference is listed as a B2i Digital Featured Conference, with company profiles available through B2i Digital. Read Press Release IndyStar indystar.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Insider Monkey insidermonkey.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Journal and Courier jconline.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Lebanon Daily News ldnews.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release MyMotherLode money.mymotherlode.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release MyMotherLode money.mymotherlode.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Nasdaq nasdaq.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release NewMediaWire newmediawire.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release NewMediaWire newmediawire.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Ocala StarBanner ocala.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Palladium-Item pal-item.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Pensacola News Journal pnj.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Pinion Newswire pinionnewswire.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release Pinion Newswire pinionnewswire.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Pinion Newswire pinionnewswire.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Record Searchlight redding.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Salinas Californian thecalifornian.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Savannah Morning News savannahnow.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Stockhouse stockhouse.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Tallahassee Democrat tallahassee.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release TechBullion techbullion.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release TechFinancials techfinancials.co.za B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Arizona Republic azcentral.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Chronicle-Journal markets.chroniclejournal.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Chronicle-Journal markets.chroniclejournal.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Columbus Dispatch dispatch.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Courier-Journal courier-journal.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Daily Record dailyrecord.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Desert Sun desertsun.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Detroit News detroitnews.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Enquirer cincinnati.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Florida Times-Union jacksonville.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Globe and Mail theglobeandmail.com DataMeds AI and Tollo Health launched the Health Lives Here mobile app, combining telehealth, pharmacy services, health data and AI-powered tools in one platform. The app launches with GLP-1 patient support and a national independent pharmacy network, with awareness driven through a partnership with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release The Globe and Mail theglobeandmail.com Lakewood-Amedex Biotherapeutics reported positive minimum inhibitory concentration data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 showed consistent antibacterial activity, with MIC values two to eight times lower than planned clinical trial doses. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Globe and Mail theglobeandmail.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release The News-Press news-press.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Northwest Florida Daily News nwfdailynews.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Patriot Ledger patriotledger.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Shelby Star shelbystar.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Stockton Record recordnet.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Topeka Capital-Journal cjonline.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release TradingView News tradingview.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release TradingView News tradingview.com The inaugural ROTH Emerging Nuclear Technology Conference takes place at 1 Hotel Central Park in New York City on October 1, 2026. Hosted by ROTH Capital Partners, it features a keynote, fireside chat, lunch panel and a full day of investor meetings covering uranium mining, small modular reactors, microreactors and fusion. B2i Digital is the Marketing Partner for this B2i Digital Featured Conference. Read Press Release Treasure Coast tcpalm.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Ventura County Star vcstar.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Visalia Times-Delta visaliatimesdelta.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release WebDisclosure webdisclosure.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Yahoo Finance finance.yahoo.com B2i Digital invites investors to the AI & Tech Virtual Investor Conference, taking place online on October 1, 2026 and hosted by Virtual Investor Conferences. Seven public companies across semiconductors, data centers, battery materials, AI-driven fintech, retail technology and online marketplaces will present live, with one-on-one investor meetings available. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release OpenPR openpr.com DataMeds AI Interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit in Las Vegas on September 28. His session, What Patients Really Want, will cover patient ownership of health data and the company's Health Lives Here initiative with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com DataMeds AI Interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit in Las Vegas on September 28. His session, What Patients Really Want, will cover patient ownership of health data and the company's Health Lives Here initiative with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com DataMeds AI Interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit in Las Vegas on September 28. His session, What Patients Really Want, will cover patient ownership of health data and the company's Health Lives Here initiative with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com DataMeds AI Interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit in Las Vegas on September 28. His session, What Patients Really Want, will cover patient ownership of health data and the company's Health Lives Here initiative with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com ZenaTech's drone subsidiary ZenaDrone advanced its defense-focused quantum navigation system for GPS-denied operations to the testing phase. Testing is underway at its facilities in Sharjah, UAE, starting with the IQ Nano indoor drone before field tests on the ZenaDrone 1000 heavy-lift cargo drone. ZenaTech is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com DataMeds AI Interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit in Las Vegas on September 28. His session, What Patients Really Want, will cover patient ownership of health data and the company's Health Lives Here initiative with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com DataMeds AI Interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit in Las Vegas on September 28. His session, What Patients Really Want, will cover patient ownership of health data and the company's Health Lives Here initiative with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release The Globe and Mail theglobeandmail.com DataMeds AI Interim Co-CEO Gerald Commissiong will present at the National Telehealth and Virtual Care Summit in Las Vegas on September 28. His session, What Patients Really Want, will cover patient ownership of health data and the company's Health Lives Here initiative with NFL Alumni Health. DataMeds AI is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Athens Banner-Herald onlineathens.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Canton Repository cantonrep.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Courier & Press courierpress.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Daytona Beach News-Journal Online news-journalonline.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Democrat and Chronicle democratandchronicle.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com ZenaTech's drone subsidiary ZenaDrone advanced its defense-focused quantum navigation system for GPS-denied operations to the testing phase. Testing is underway at its facilities in Sharjah, UAE, starting with the IQ Nano indoor drone before field tests on the ZenaDrone 1000 heavy-lift cargo drone. ZenaTech is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release IndyStar indystar.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Journal and Courier jconline.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Lebanon Daily News ldnews.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com ZenaTech's drone subsidiary ZenaDrone advanced its defense-focused quantum navigation system for GPS-denied operations to the testing phase. Testing is underway at its facilities in Sharjah, UAE, starting with the IQ Nano indoor drone before field tests on the ZenaDrone 1000 heavy-lift cargo drone. ZenaTech is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Palladium-Item pal-item.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com ZenaTech's drone subsidiary ZenaDrone advanced its defense-focused quantum navigation system for GPS-denied operations to the testing phase. Testing is underway at its facilities in Sharjah, UAE, starting with the IQ Nano indoor drone before field tests on the ZenaDrone 1000 heavy-lift cargo drone. ZenaTech is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Courier-Journal courier-journal.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Enquirer cincinnati.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Florida Times-Union jacksonville.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Globe and Mail theglobeandmail.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Patriot Ledger patriotledger.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Ventura County Star vcstar.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Visalia Times-Delta visaliatimesdelta.com Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers. Nu-3 is a topical Bisphosphocin antimicrobial, and topline data from the study are expected in the first quarter of 2027. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Athens Banner-Herald onlineathens.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Canton Repository cantonrep.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Courier & Press courierpress.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Daytona Beach News-Journal Online news-journalonline.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Democrat and Chronicle democratandchronicle.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release IndyStar indystar.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Journal and Courier jconline.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Lebanon Daily News ldnews.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Ocala StarBanner ocala.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Palladium-Item pal-item.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release TechBullion techbullion.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release TechFinancials techfinancials.co.za 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Enquirer cincinnati.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Ventura County Star vcstar.com Phio Pharmaceuticals will present a clinical development update at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania. CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma, its planned next stage and the INTASYL platform. Phio Pharmaceuticals is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Athens Banner-Herald onlineathens.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Canton Repository cantonrep.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Courier & Press courierpress.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Daytona Beach News-Journal Online news-journalonline.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Democrat and Chronicle democratandchronicle.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release FinanzWire finanzwire.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Insider Monkey insidermonkey.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Insider Monkey insidermonkey.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Journal and Courier jconline.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Lebanon Daily News ldnews.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Ocala StarBanner ocala.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Pinion Newswire pinionnewswire.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release TechBullion techbullion.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release TechFinancials techfinancials.co.za Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release TechFinancials techfinancials.co.za Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Courier-Journal courier-journal.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Enquirer cincinnati.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Florida Times-Union jacksonville.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Patriot Ledger patriotledger.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Ventura County Star vcstar.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release Visalia Times-Delta visaliatimesdelta.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release WebDisclosure webdisclosure.com 374Water will present new AirSCWO destruction-efficiency data at WEFTEC 2026 in New Orleans. The results show greater than 99.4% PFAS destruction and greater than 99.99% destruction of the tire-derived contaminant 6PPD-Q, and company executives will be at booth 2254. 374Water is a B2i Digital Featured Company. Read Press Release WebDisclosure webdisclosure.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release WebDisclosure webdisclosure.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com Live Presentations and Q A Across Community and Regional Banking Wealth Management Logistics Real Estate and Bitcoin Treasury Companies From US UK and Canadian Markets Present Live Online with Repl... Read Press Release Akron Beacon Journal beaconjournal.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Akron Beacon Journal beaconjournal.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Athens Banner-Herald onlineathens.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Canton Repository cantonrep.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Courier & Press courierpress.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Democrat and Chronicle democratandchronicle.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Detroit Free Press freep.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com DataMEDS AI launched its new corporate website, DataMedsAI.com, along with updated branding. The relaunch follows its acquisition of Helomics and a litigation settlement that extinguished about $19 million in liabilities, as it prepares to soft launch the Health Lives Here app. DataMeds AI is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release EIN Presswire einpresswire.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com DataMEDS AI launched its new corporate website, DataMedsAI.com, along with updated branding. The relaunch follows its acquisition of Helomics and a litigation settlement that extinguished about $19 million in liabilities, as it prepares to soft launch the Health Lives Here app. DataMeds AI is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com B2i Digital invites investors to the Financial Services Virtual Investor Conference, taking place online on September 24, 2026 and hosted by Virtual Investor Conferences. Presenting companies span community and regional banking, wealth management, logistics real estate and bitcoin treasury firms from US, UK and Canadian markets. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release FinancialContent financialcontent.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release FinancialContent financialcontent.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Florida Today floridatoday.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Gainesville Sun gainesville.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release IndyStar indystar.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release IndyStar indystar.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Insider Monkey insidermonkey.com B2i Digital invites investors to the Financial Services Virtual Investor Conference, taking place online on September 24, 2026 and hosted by Virtual Investor Conferences. Presenting companies span community and regional banking, wealth management, logistics real estate and bitcoin treasury firms from US, UK and Canadian markets. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release Insider Monkey insidermonkey.com Lakewood-Amedex Biotherapeutics obtained central and all site Institutional Review Board approvals and confirmed clinical site readiness for its Phase 2a trial of Nu-3. The trial will evaluate the safety and efficacy of Nu-3 in patients with mildly infected diabetic foot ulcers. Lakewood-Amedex is a new B2i Digital Featured Company. Read Press Release Journal and Courier jconline.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Lancaster Eagle-Gazette lancastereaglegazette.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Lebanon Daily News ldnews.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com DataMEDS AI launched its new corporate website, DataMedsAI.com, along with updated branding. The relaunch follows its acquisition of Helomics and a litigation settlement that extinguished about $19 million in liabilities, as it prepares to soft launch the Health Lives Here app. DataMeds AI is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com B2i Digital invites investors to the Financial Services Virtual Investor Conference, taking place online on September 24, 2026 and hosted by Virtual Investor Conferences. Presenting companies span community and regional banking, wealth management, logistics real estate and bitcoin treasury firms from US, UK and Canadian markets. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release MyMotherLode money.mymotherlode.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release MyMotherLode money.mymotherlode.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Ocala StarBanner ocala.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release OpenPR openpr.com DataMEDS AI launched its new corporate website, DataMedsAI.com, along with updated branding. The relaunch follows its acquisition of Helomics and a litigation settlement that extinguished about $19 million in liabilities, as it prepares to soft launch the Health Lives Here app. DataMeds AI is a B2i Digital Featured Company. Read Press Release Palladium-Item pal-item.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Palladium-Item pal-item.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Pensacola News Journal pnj.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Pinion Newswire pinionnewswire.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Record Searchlight redding.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Salinas Californian thecalifornian.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Savannah Morning News savannahnow.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Tallahassee Democrat tallahassee.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release TechBullion techbullion.com B2i Digital invites investors to the Financial Services Virtual Investor Conference, taking place online on September 24, 2026 and hosted by Virtual Investor Conferences. Presenting companies span community and regional banking, wealth management, logistics real estate and bitcoin treasury firms from US, UK and Canadian markets. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Arizona Republic azcentral.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Arizona Republic azcentral.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com DataMEDS AI launched its new corporate website, DataMedsAI.com, along with updated branding. The relaunch follows its acquisition of Helomics and a litigation settlement that extinguished about $19 million in liabilities, as it prepares to soft launch the Health Lives Here app. DataMeds AI is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com B2i Digital invites investors to the Financial Services Virtual Investor Conference, taking place online on September 24, 2026 and hosted by Virtual Investor Conferences. Presenting companies span community and regional banking, wealth management, logistics real estate and bitcoin treasury firms from US, UK and Canadian markets. B2i Digital is the Official Marketing Partner for this B2i Digital Featured Conference. Read Press Release The Chronicle-Journal markets.chroniclejournal.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Chronicle-Journal markets.chroniclejournal.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Columbus Dispatch dispatch.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Courier-Journal courier-journal.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Courier-Journal courier-journal.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Daily Record dailyrecord.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Desert Sun desertsun.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Detroit News detroitnews.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Enquirer cincinnati.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Enquirer cincinnati.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Florida Times-Union jacksonville.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Florida Times-Union jacksonville.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The News-Press news-press.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Northwest Florida Daily News nwfdailynews.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Patriot Ledger patriotledger.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Patriot Ledger patriotledger.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Shelby Star shelbystar.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release The Stockton Record recordnet.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Topeka Capital-Journal cjonline.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Treasure Coast tcpalm.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Ventura County Star vcstar.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release Visalia Times-Delta visaliatimesdelta.com Kolibri Global Energy completed fracture stimulation on all three Clifton Mack wells, with flowback expected shortly and early production rates anticipated in the coming weeks. The company also finished drilling its first False Caney bench test well and renewed its share buyback for up to about 1.8 million shares. Kolibri Global Energy is a B2i Digital Featured Company. Read Press Release Visalia Times-Delta visaliatimesdelta.com Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper issued a letter to shareholders reviewing recent clinical, corporate and financial achievements. Highlights include a $7.5 million private placement, positive preclinical safety data supporting Phase 2a dose selection for Nu-3 Gel, and the company's Nasdaq listing under the ticker LABT. Lakewood-Amedex is a B2i Digital Featured Company. Read Press Release TechFinancials techfinancials.co.za B2i Digital is hosting a Financial Services Virtual Investor Conference on September 24, 2026, featuring five companies from banking, real estate, and Bitcoin sectors. Financial services companies ... Read Press Release Barchart barchart.com Public and private nuclear companies meet institutional investors at the StoneX Nuclear Innovation Summit (September 23-24, 2026) in Knoxville; B2i Digital highlights the summit to a 330 million monthly media audience and 1.7 million investors. Read Press Release FinancialContent financialcontent.com B2i Digital announces Canadian Phosphate Limited (ASX: CP8 | OTCQB: CPHOF) as its newest Featured Company, an Australian firm building a phosphate business across North America in a mineral classified as critical by the US, Canada and EU. Read Press Release TechFinancials techfinancials.co.za B2i Digital named Canadian Phosphate Limited as a Featured Company. The Australian phosphate exploration firm operates projects in British Columbia and Utah, with assay results expected in Septembe... Read Press Release EIN Presswire einpresswire.com Canadian Phosphate Limited became a B2i Digital Featured Company to reach North American investors. The mineral exploration company is drilling for phosphate in British Columbia and acquired a proj... Read Press Release OpenPR openpr.com Public and private nuclear companies meet institutional investors in Knoxville, Tennessee, with panels, one-on-one meetings and a visit to Oak Ridge National Laboratory. Read Press Release TechBullion techbullion.com ZenaTech has been selected as a qualified supplier for Canada's Defence Drone Initiative Marketplace, positioning the company to compete for future defense and security drone contracts with the Can... Read Press Release Finanznachrichten finanznachrichten.de B2i Digital announced Canadian Phosphate Limited as a Featured Company. The Australian mineral exploration company is developing phosphate projects in British Columbia and Utah, with assay results ... Read Press Release OpenPR openpr.com B2i Digital announced Canadian Phosphate Limited as a featured company. The Australian mineral exploration firm is developing phosphate projects in British Columbia and Utah, with assay results exp... Read Press Release Business Insider markets.businessinsider.com Three 121 Mining Investment events (New York, Global Online, London) named B2i Digital Featured Conferences, with B2i Digital providing marketing support for all three across its media network. Read Press Release TechFinancials techfinancials.co.za B2i Digital is providing marketing support for three 121 Mining Investment conferences in New York (September 17), online (October 13-14), and London (November 23-24). The events connect mining com... Read Press Release WebDisclosure webdisclosure.com Three 121 Mining Investment events have been named B2i Digital Featured Conferences, connecting mining companies with institutional investors in New York. Read Press Release Insider Monkey insidermonkey.com B2i Digital is providing marketing support for three 121 Mining Investment conferences in New York (September 17), online (October 13-14), and London (November 23-24). The events connect mining com... Read Press Release OpenPR openpr.com B2i Digital provides marketing support for the BHP Xplor and 121 Mining Investment Showcase in New York, raising visibility for participating mining companies. Read Press Release The Globe and Mail theglobeandmail.com Three 121 Mining Investment events (New York, Global Online, London) named B2i Digital Featured Conferences; B2i Digital's media network spans 800+ outlets with a 330 million+ combined monthly audience. Read Press Release OpenPR openpr.com Vancouver British Columbia Rocket Doctor AI Inc CSE AIDR OTC AIRDF Frankfurt 939 Rocket Doctor AI or the Company a physician built AI powered healthcare technology company focused on empowering doc... Read Press Release EIN Presswire einpresswire.com B2i Digital is providing marketing support for three 121 Mining Investment events: BHP Xplor x 121 in New York on September 17, 121 Global Online on October 13-14, and 121 London on November 23-24.... Read Press Release Insider Monkey insidermonkey.com B2i Digital is hosting a Life Sciences Virtual Investor Forum on September 17, 2026, featuring seven public companies presenting on oncology, drug delivery, antibiotics, and other therapeutic areas... Read Press Release TechFinancials techfinancials.co.za Life sciences companies will present at a virtual investor forum on September 17, 2026, featuring presentations on oncology, drug delivery, antibiotics, and other therapeutics. Seven public compani... Read Press Release The AI Journal aijourn.com Aerospace and defense management teams will meet with investors at two events in New York City on September 9-10, 2026: the Defending Our Nation Leadership Forum and the 32nd Annual Gabelli Aerospa... Read Press Release Barchart barchart.com B2i Digital welcomes Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) as its newest Featured Company; the Sarasota clinical-stage biotech develops the Bisphosphocin class of broad-spectrum antimicrobials for antibiotic-resistant infections. Read Press Release Business Insider markets.businessinsider.com B2i Digital welcomes Lakewood-Amedex Biotherapeutics as a Featured Company, partnering with conferences, public companies and capital markets advisors through its Featured Conference, Featured Company and Featured Expert programs. Read Press Release Nasdaq nasdaq.com Lakewood-Amedex Biotherapeutics is named a B2i Digital Featured Company, with the campaign centering on Nu-3, its upcoming Phase 2a trial, and the Bisphosphocin antimicrobial class behind it. Read Press Release Benzinga benzinga.com 374Water reported Q2 2026 revenue of $2.26 million, up 280% year-over-year, driven by completion of the Orange County Sanitation District project milestone. The cleantech company achieved 87% gross... Read Press Release Benzinga benzinga.com DataMeds AI announced that its pharmacy subsidiary Corexa Health achieved key milestones including GLP-1 drug availability through TrumpRx, launch of CorexaRx.com online store, and integration into... Read Press Release Benzinga benzinga.com Unicycive Therapeutics reports second quarter 2026 financial results and a business update. Unicycive Therapeutics is a B2i Digital Featured Company. Read Press Release Benzinga benzinga.com 374Water reported preliminary Q2 2026 revenue of $2.2 million, more than tripling from $0.6 million in Q2 2025. The company advanced commercial deployments including completing a factory acceptance... Read Press Release USA Today usatoday.com Rocket Doctor AI joins the B2i Digital Featured Company Program, with B2i Digital building a featured company profile, running paid digital advertising and distributing content to its 1.7 million-participant network. Read Press Release StreetInsider streetinsider.com Rocket Doctor AI (CSE: AIDR, OTC: AIRDF) retains B2i Digital under a digital advisory agreement, joining the B2i Digital Featured Company Program and its network of more than 1.7 million retail and institutional market participants. Read Press Release The Globe and Mail theglobeandmail.com Rocket Doctor AI has retained B2i Digital to provide digital marketing advisory services and join its Featured Company Program, which reaches 1.7 million retail and institutional investors. The thr... Read Press Release Barchart barchart.com Rocket Doctor AI joins the B2i Digital Featured Company Program, with B2i Digital providing investor-focused digital marketing advisory services, a featured company profile, paid advertising and email campaigns to its 1.7 million-participant network. Read Press Release The AI Journal aijourn.com Rocket Doctor AI has joined B2i Digital's Featured Company Program, gaining access to a network of 1.7 million retail and institutional investors. The company will receive digital marketing advisor... Read Press Release The Detroit News detroitnews.com New Prime Contractor Relationship Expands Safe Pro’s Growing Network of Leading Defense Sector Relationships Safe Pro Read Press Release Barchart barchart.com Safe Pro Group receives a $780,000 purchase order for a Department of War package of edge AI-powered threat mapping and Blue UAS drones, with B2i Digital listed among investor contacts. Read Press Release Nasdaq nasdaq.com Rocket Doctor AI has entered a digital marketing advisory agreement with B2i Digital to promote its AI-powered healthcare solutions to over 1.7 million retail and institutional investors. The three... Read Press Release BNN Bloomberg bnnbloomberg.ca Rocket Doctor AI has joined B2i Digital's Featured Company Program to receive digital marketing advisory services across multiple platforms. The agreement, worth $21,375 USD for three months, will ... Read Press Release USA Today usatoday.com B2i Digital announces the Precious Metals and Critical Minerals Virtual Investor Conference (July 22-23, 2026), citing a proprietary network of more than 1.7 million retail and institutional market participants. Read Press Release TradingView News tradingview.com Life sciences public companies present at the June 24-25 Life Sciences Virtual Investor Forum co-hosted by Zacks Small-Cap Research, with B2i Digital as Official Marketing Partner reaching 1.7 million+ market participants. Read Press Release Nasdaq nasdaq.com B2i Digital invites investors to the two-day Life Sciences Virtual Investor Forum (June 24-25, 2026), a B2i Digital Featured Conference co-hosted by Virtual Investor Conferences and Zacks Small-Cap Research. Read Press Release NewMediaWire newmediawire.com B2i Digital named CitroTech Inc. a Featured Company. CitroTech develops EPA-recognized, environmentally safe fire inhibitors made from food-grade ingredients for wildfire prevention and wood produc... Read Press Release TradingView News tradingview.com B2i Digital welcomes CitroTech Inc. (NYSE American: CITR) as a Featured Company; the specialty chemical firm makes the only EPA Safer Choice-recognized long-term fire inhibitor and formed a 50/50 JV with Hexion. Read Press Release Nasdaq nasdaq.com B2i Digital named CitroTech Inc. a Featured Company. CitroTech produces EPA-approved, environmentally safe fire inhibitors made from food-grade ingredients for wildfire and wood product protection.... Read Press Release EIN Presswire einpresswire.com B2i Digital joins 121 Mining Investment New York (June 15-16, 2026) as Official Marketing Partner; 300+ investors and 1,000+ pre-arranged meetings with 70+ mining companies at Convene Manhattan. Read Press Release KDH News kdhnews.com B2i Digital named Official Marketing Partner of 121 Mining Investment New York (June 15-16, 2026), with 300+ investors and 1,000+ pre-arranged one-on-one meetings, syndicated to the Killeen Daily Herald local news site. Read Press Release The Globe and Mail theglobeandmail.com B2i Digital has been named official marketing partner for the 121 Mining Investment New York conference on June 15-16, 2026. The event will connect over 300 investors with more than 70 mining compa... Read Press Release NewMediaWire newmediawire.com B2i Digital has become the official marketing partner for 121 Mining Investment New York, a June 15-16 conference connecting over 70 mining companies with 300+ investors for one-on-one meetings and... Read Press Release NewMediaWire newmediawire.com B2i Digital named Renforth Resources Inc., a Quebec-based gold and critical minerals explorer, as a Featured Company. Renforth owns two deposits near Malartic: the Parbec gold deposit and Victoria ... Read Press Release The Globe and Mail theglobeandmail.com B2i Digital named Renforth Resources Inc., a Quebec-based gold and critical minerals explorer, as a Featured Company. Renforth owns two deposits near Malartic: the Parbec gold deposit and the Victo... Read Press Release Yahoo Finance finance.yahoo.com B2i Digital names Renforth Resources Inc. a Featured Company, highlighting its Parbec gold deposit and Victoria nickel-polymetallic system in Quebec's Abitibi region. Read Press Release Nasdaq nasdaq.com B2i Digital returns as Marketing Partner for the 16th Annual ROTH London Conference, June 16-18, 2026, running its Featured Conference program to extend the reach of 80+ presenting growth companies to its 1.6 million-participant network. Read Press Release Yahoo Finance finance.yahoo.com B2i Digital will serve as Official Marketing Partner for Centurion One Capital's Miami Summit on May 28, 2026 at the Faena Hotel Miami Beach, connecting growth-stage issuers with institutional investors and family offices. Read Press Release The Globe and Mail theglobeandmail.com B2i Digital announced a Precious Metals & Critical Minerals Hybrid Conference on May 21, 2026, at OTC Markets Headquarters in Manhattan with simultaneous global online broadcast. The event features... Read Press Release NewMediaWire newmediawire.com B2i Digital named Precipio, Inc., a cancer diagnostics biotechnology company, as a Featured Company. Precipio operates pathology services and a products business, achieving 30% revenue growth and p... Read Press Release Quantum Zeitgeist quantumzeitgeist.com B2i Digital is hosting an April 23 virtual investor conference featuring 30-minute presentations from ten technology companies spanning quantum cryptography, AI healthcare, and data centers. Invest... Read Press Release NewMediaWire newmediawire.com B2i Digital is the official marketing partner for OTC Markets Group's Oil & Gas Virtual Investor Conference on April 16, 2026, featuring 12 energy companies presenting live to investors. The event ... Read Press Release Global Fintech Series globalfintechseries.com Ethema Health Corporation appointed James M. Poage as Chief Financial Officer, effective March 30, 2026. Poage is a Senior Financial Analyst who will lead the company's financial operations. Read Press Release The Globe and Mail theglobeandmail.com Algorhythm Holdings (NASDAQ: RIME) named a B2i Digital Featured Company to share the SemiCab AI logistics story with retail and institutional investors; platform has cut empty freight miles 70% for Fortune 500 shippers. Read Press Release Yahoo Finance finance.yahoo.com B2i Digital named Marketing Partner for the 2026 Centri Capital Conference at Nasdaq MarketSite on April 14, 2026, showcasing 50+ emerging growth companies to 500+ attendees through its Featured Conference program. Read Press Release The Globe and Mail theglobeandmail.com B2i Digital highlights the Banking Virtual Investor Conference on March 26, 2026, co-hosted by Alliance Advisors, as a B2i Digital Featured Conference featuring 10 community banks and financial holding companies. Read Press Release FinancialContent financialcontent.com B2i Digital features the Banking Virtual Investor Conference on March 26, 2026, co-hosted by Alliance Advisors, with executive presentations from 10 community banks and financial holding companies. Read Press Release NewMediaWire newmediawire.com B2i Digital is highlighting the OTCQX Best 50 Virtual Investor Conference on March 19, 2026, featuring executive presentations from 11 top-performing companies. The event offers investors live pres... Read Press Release The Globe and Mail theglobeandmail.com B2i Digital announced MySize, Inc. as a featured company. MySize operates three fashion-tech platforms addressing returns and excess inventory: Naiz Fit for sizing guidance, Percentil for secondhan... Read Press Release Yahoo Finance finance.yahoo.com B2i Digital welcomes MySize, Inc. as a Featured Company, focusing on two costly problems in online fashion: wrong-size purchases driving returns, and excess inventory across its Naiz Fit, Percentil and Orgad businesses. Read Press Release NewMediaWire newmediawire.com Phio Pharmaceuticals was selected as a B2i Digital Featured Company. The clinical-stage biotech company reported its PH-762 cancer therapy achieved approximately 65% pathological response in skin c... Read Press Release The Globe and Mail theglobeandmail.com Phio Pharmaceuticals Corp. is selected as a B2i Digital Featured Company, highlighting its INTASYL siRNA gene-silencing platform and lead candidate PH-762 in cutaneous squamous cell carcinoma and melanoma. Read Press Release NewMediaWire newmediawire.com B2i Digital will serve as Official Marketing Partner for the AI & Technology Virtual Investor Conference on February 19, 2026, hosted by Virtual Investor Conferences. The event connects public comp... Read Press Release Yahoo Finance finance.yahoo.com B2i Digital will serve as Official Marketing Partner for the AI & Technology Virtual Investor Conference on February 19, 2026, hosted by Virtual Investor Conferences. The platform enables public co... Read Press Release The Chronicle-Journal markets.chroniclejournal.com B2i Digital will serve as official marketing partner for the AI & Technology Virtual Investor Conference on February 19, 2026, hosted by Virtual Investor Conferences. The platform enables public co... Read Press Release CityBuzz citybuzz.co B2i Digital will serve as Official Marketing Partner for Virtual Investor Conferences' AI & Technology Virtual Investor Conference on February 19, 2026. The partnership connects AI and technology c... Read Press Release Yahoo Finance finance.yahoo.com Ethema Health Corporation is named a B2i Digital Featured Company. The partnership showcases Ethema's substance use disorder treatment network across Florida and Kentucky, with roughly 400 available beds and 2025 revenue expected at $19.5 million. Read Press Release TradingView News tradingview.com Jupiter Neurosciences, a clinical-stage pharmaceutical company advancing a Phase IIa Parkinson's disease trial, was selected as a B2i Digital Featured Company. The company targets neuroinflammation... Read Press Release EQS News eqs-news.com Jupiter Neurosciences (Nasdaq: JUNS) selected as a B2i Digital Featured Company, with B2i Digital supporting investor awareness for the neuroscience company. Read Press Release NewMediaWire newmediawire.com B2i Digital has been named Official Marketing Partner for OTC Markets Group's Precious Metals & Critical Minerals Virtual Investor Conference, taking place February 10-12, 2026. The event connects ... Read Press Release Nasdaq nasdaq.com B2i Digital has been named Official Marketing Partner for OTC Markets Group's Precious Metals & Critical Minerals Virtual Investor Conference, taking place February 10-12, 2026. The event connects ... Read Press Release The Globe and Mail theglobeandmail.com B2i Digital has been named Official Marketing Partner for OTC Markets Group's Precious Metals & Critical Minerals Virtual Investor Conference taking place February 10-12, 2026. The event connects m... Read Press Release Nasdaq nasdaq.com B2i Digital, Official Marketing Partner for Virtual Investor Conferences, supports presenting companies at the Small Cap Growth Virtual Investor Conference on February 5, 2026, featuring 12 global small-cap issuers across NYSE, Nasdaq, TSX, CSE, ASX and Euronext. Read Press Release National Law Review natlawreview.com B2i Digital will continue as the official marketing partner for OTC Markets Group's Virtual Investor Conferences in 2026, supporting 12 sector-focused events across digital assets, technology, clea... Read Press Release Nasdaq nasdaq.com B2i Digital has been named Official Marketing Partner for the Digital Asset Virtual Investor Conference on January 27, 2026. The event connects publicly traded blockchain and digital asset companie... Read Press Release FinancialContent financialcontent.com B2i Digital is named Official Marketing Partner for the Digital Asset Virtual Investor Conference on January 27, 2026, the first sector-focused VIC event of the 2026 calendar. Read Press Release NewMediaWire newmediawire.com B2i Digital will continue as the Official Marketing Partner for OTC Markets Group's Virtual Investor Conferences in 2026, supporting 12 sector-focused events across digital assets, precious metals,... Read Press Release Yahoo Finance finance.yahoo.com B2i Digital will continue as the Official Marketing Partner for OTC Markets Group's Virtual Investor Conferences in 2026, supporting 12 sector-focused events including digital assets, precious meta... Read Press Release FinancialContent financialcontent.com B2i Digital continues as Official Marketing Partner for OTC Markets Group's Virtual Investor Conferences in 2026, supporting 12 sector-focused events spanning digital assets, critical minerals, AI, clean energy, life sciences, banking and oil and gas. Read Press Release Yahoo Finance finance.yahoo.com Genvor Inc., an agricultural biotechnology company, has joined B2i Digital's platform as a Featured Company to increase investor awareness of its AI-accelerated peptide technology for sustainable c... Read Press Release The Globe and Mail theglobeandmail.com Genvor Inc. partners with B2i Digital as a Featured Company, highlighting its AI-accelerated peptide design for crop protection and its USDA co-assigned patent for antifungal peptide AGM182. Read Press Release FinancialContent financialcontent.com Genvor Inc. partners with B2i Digital as a Featured Company to expand investor awareness of its BioCypher Algorithm and antimicrobial, insecticidal and nutrient-enhancing peptide portfolio. Read Press Release The Globe and Mail theglobeandmail.com B2i Digital has been selected as marketing partner for DealFlow Events' Discovery Conference, scheduled for January 28-29, 2026, in Atlantic City. The event will feature over 200 high-growth public... Read Press Release Investing.com investing.com SuperCom Ltd. (NASDAQ: SPCB), a Tel Aviv-based provider of electronic monitoring solutions, joins B2i Digital as a Featured Company amid growth in its government monitoring contracts. Read Press Release Yahoo Finance finance.yahoo.com SuperCom Ltd., a Tel Aviv-based electronic monitoring solutions provider, has been named a featured company by B2i Digital to increase investor awareness. The partnership aims to help SuperCom comm... Read Press Release The Globe and Mail theglobeandmail.com SuperCom Ltd., a Tel Aviv-based electronic monitoring solutions provider, was named a B2i Digital Featured Company to expand investor awareness. The partnership aims to communicate SuperCom's value... Read Press Release FinancialContent financialcontent.com SuperCom Ltd. partners with B2i Digital as a Featured Company, highlighting its PureSecurity Suite of electronic offender monitoring solutions for governments across Europe and North America. Read Press Release FinancialContent financialcontent.com The Benchmark Company names B2i Digital Marketing Partner for its 14th Annual Discovery One-on-One Investor Conference on December 4, 2025 at the New York Athletic Club, expanding awareness to B2i's 1.4 million-investor network. Read Press Release Nasdaq nasdaq.com Applied DNA Sciences (NASDAQ: BNBX) named a B2i Digital Featured Company, leveraging B2i Digital's investor network to share its strategic rebrand and BNB-focused digital asset treasury strategy with investors. Read Press Release Yahoo Finance finance.yahoo.com Applied DNA Sciences becomes a B2i Digital Featured Company to share its strategic rebrand and yield-focused BNB digital asset treasury strategy with investors following its ticker change to BNBX. Read Press Release StreetInsider streetinsider.com YY Group Holding (NASDAQ: YYGH) partners with B2i Digital for an investor awareness program, presenting its on-demand staffing and integrated facility management platforms serving 300+ clients in 12 countries. Read Press Release Investing.com investing.com B2i Digital names YY Group Holding Limited (NASDAQ: YYGH) a B2i Digital Featured Company to boost investor visibility for its on-demand staffing and integrated facility management platforms. Read Press Release Yahoo Finance finance.yahoo.com YY Group Holding Limited partnered with B2i Digital to increase investor awareness of its on-demand staffing and integrated facility management platforms serving over 300 clients across twelve coun... Read Press Release StreetInsider streetinsider.com YY Group Holding Limited partners with B2i Digital to expand investor awareness of its YY Circle Super App and YY Smart iClean IoT facility management platforms across 12 countries. Read Press Release FinancialContent financialcontent.com YY Group Holding Limited partners with B2i Digital to expand investor awareness of its intelligent labor sourcing and IoT-enabled integrated facility management technology platforms. Read Press Release The Globe and Mail theglobeandmail.com Heidmar Maritime Holdings Corp. partners with B2i Digital as a Featured Company, spotlighting its four-decade track record in tanker pool and commercial management services across 39 commercially managed vessels. Read Press Release Yahoo Finance finance.yahoo.com B2i Digital serves again as marketing partner for the 15th Annual ROTH London Conference, an invite-only event connecting management from approximately 70 companies with institutional investors. Read Press Release Yahoo Finance finance.yahoo.com OceanPal Inc. partners with B2i Digital as a Featured Company, with the campaign highlighting its global shipping platform and debt-free balance sheet. Read Press Release AP News apnews.com B2i Digital selected as Marketing Partner for The Benchmark Company's 13th Annual Discovery One-on-One Conference (December 11, 2024), showcasing participating company profiles to its community of over 1.1 million investors. Read Press Release European Business Magazine europeanbusinessmagazine.com ALT5 Sigma Corporation will present at Spartan Capital Securities' inaugural investor conference on November 4th at the Pierre Hotel in New York, showcasing its growth strategy and market position ... Read Press Release StreetInsider streetinsider.com The Nuvo Group is recognized as a B2i Digital Featured Expert, joining the program alongside B2i Digital's Featured Company and Featured Conference offerings. Read Press Release Big News Network bignewsnetwork.com B2i Digital confirmed as Marketing Partner for the 3rd Annual ROTH Healthcare Opportunities Conference, introducing presenting companies to B2i Digital's network of 900,000+ investors. Read Press Release Big News Network bignewsnetwork.com B2i Digital established as Marketing Partner for Maxim Group's 2024 Gaming, Media and Entertainment Virtual Conference, creating company profiles on b2idigital.com and running targeted digital marketing campaigns. Read Press Release Yahoo Finance finance.yahoo.com Beneficient joins the B2i Digital family of Featured Companies, promoting its technology-enabled platform offering exit, primary capital, trust and custody solutions to alternative asset holders. Read Press Release Benzinga benzinga.com Spartan Capital Securities and B2i Digital announce the Spartan Capital Investor Conference 2024, with B2i Digital providing marketing support and investor outreach for the event. Read Press Release Nasdaq nasdaq.com B2i Digital is named Gold Sponsor and marketing partner for Maxim Group's virtual conference, The Next Frontier: Bitcoin Mining in a Post-Halving Era, connecting miners with retail and institutional investors. Read Press Release StreetInsider streetinsider.com Starco Brands partners with B2i Digital to enhance shareholder communication, with B2i Digital building an in-depth company profile and facilitating dialogue between investors and management. Read Press Release Nasdaq nasdaq.com LE Worldwide Limited engages B2i Digital for a digital investor engagement and awareness program highlighting its smart horticulture LED lighting business and anticipated SPAC merger with Ace Global Business Acquisition. Read Press Release

Matchmaking starts with a conversation.

A short call is enough to understand your goals, your story, and how our network reaches the investors who should hear it.

Let's Talk Learn More About B2i

Explore b2i Digital

featured-conferences-badge

B2i Digital partners with conferences like ROTH, Benchmark, Ladenburg Thalmann, OTC Markets, and the NYSE Growth Equity Symposium to connect the online and offline worlds.

Browse Conferences
featured-companies-badge

Dig into each company's unique story, bios, and filed documents.

View Featured Companies
featured-experts-badge

Industry experts vetted by B2i, providing hands-on support to active market companies.

Meet Our Experts
B2i Media Network

From Nasdaq to USA Today, see where client stories land and the audience behind them.

SEE THE MEDIA NETWORK

B2i Digital Spotlight

Featured Company

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT)

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains including MRSA and VRE.

View Company

Featured Conference

Growth Equity Symposium

The NYSE Growth Equity Symposium comes to 11 Wall Street on November 30, 2026. The event features NYSE-led educational programming and networking between investors and emerging growth issuers. The program concludes with a cocktail reception.

View Conference

SVG_partner-horizontal-color      B2i Digital Google Partner

© 2026 B2I DIGITAL, Inc.